Last edition
News about "Joenja "
Pharming Launches Joenja in Japan for APDS Patients Aged 4 and Older
Pharming has launched Joenja in Japan for APDS patients aged 4 years and older, making Japan the first market to offer the treatment commercially to children aged 4–11.
Joenja | 14/08/2026 | By News Bureau
Pharming Launches Joenja in Japan for APDS Patients Aged 4 Years and Older
Pharming has launched Joenja (leniolisib) in Japan for adults and children aged 4 years and older with APDS, marking its first commercial availability for children aged 4 to 11 years.
Joenja | 13/08/2026 | By News Bureau
Pharming Secures EU Approval for Joenja as First Targeted Treatment for Rare Immune Disorder APDS
Pharming Group has received European Commission approval for Joenja, expanding treatment access for patients with activated PI3K delta syndrome and strengthening therapeutic options for rare immune disorders.
Joenja | 26/05/2026 | By News Bureau | 104
Pharming Gets Complete Response Letter from US FDA for Joenja
The US FDA issued a Complete Response Letter to Pharming Group for the supplemental NDA for Joenja, citing the need for additional information to support its use in children aged four to 11 years with activated phosphoinositide 3-kinase delta syndrome, a rare primary immunodeficiency.
Joenja | 02/02/2026 | By News Bureau | 219
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy